Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’.

PDOs provide a step-change improvement in the ability to screen drugs in models that are predictive of patient responses to those drugs, providing better data today and better drugs tomorrow.

  • Derived in the lab from normal subjects or patient biopsy tissue from a wide variety of disease states 
  • 3D clusters, self-assembled from adult stem cells with no planar plasticisation 
  • Contain multiple cell-types 
  • Mimic source organ/tissue architecture to duplicate normal or disease pathology 

Cellesce’s leading technology can: 

Produce millions of reproducible PDOs per manufacturing batch using its patented bioprocess and bioreactors. 

faithful and predictive

Genetically diverse

Can be used in diagnostics and personalised medicine

genetically diverse

Faithful & predictive

Can model by tumour or mutation subtype

Multicellular & 3D

Can be used in diagnostics and personalised medicine

Model major tissue types

Wide range of cancer types, normal tissue – other therapies

Scalable & consistent

Can be used in high throughput applications

Can add immune cells

Can use in immune & cell therapy applications

The Cellesce Organoid Expansion Process

Cellesce has invented and patented a novel bioprocess for the expansion of PDOs for a multitude of applications including drug discovery, biological drug targeting and organ-on-a-chip applications.

Until recently, organoids could only be grown and expanded manually. This is a technically challenging, time-consuming, and labour-intensive process resulting in small numbers of PDOs with inconsistent performance. This has previously limited PDO suitability for use in high throughput and other applications by pharma and biotech.

manual culture v bioprocess

The patented Cellesce bioprocess has enabled a massive increase in PDO production compared to manual processes. Furthermore, better process controls utilising in-line sensors and real-time monitoring ensure precise culture conditions, improved yield and control of PDO size and reduced batch-to-batch, user-to-user variability. Cellesce’s significant improvement to existing bulk culture methods has finally enabled PDOs for drug discovery and development.

Cellesce bioprocess development